Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Bioregenx (BRGX) EBITDA Margin (2022 - 2025)

Bioregenx's EBITDA Margin history spans 4 years, with the latest figure at 263.93% for Q4 2025.

  • Quarterly results put EBITDA Margin at 263.93% for Q4 2025, up 373109.0% from a year ago — trailing twelve months through Dec 2025 was 83.34% (up 90170.0% YoY), and the annual figure for FY2025 was 83.34%, up 90170.0%.
  • EBITDA Margin for Q4 2025 was 263.93% at Bioregenx, down from 14.44% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 161.38% in Q3 2022 to a low of 3995.01% in Q4 2024.
  • The 4-year median for EBITDA Margin is 66.16% (2023), against an average of 407.2%.
  • The sharpest move saw EBITDA Margin crashed -395701bps in 2024, then skyrocketed 373109bps in 2025.
  • Year by year, EBITDA Margin stood at 62.09% in 2022, then surged by 39bps to 38.01% in 2023, then plummeted by -10411bps to 3995.01% in 2024, then soared by 93bps to 263.93% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 263.93%, 14.44%, and 41.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.